Clinical Trials Browser

Phase 3 × HBM9161 × 90 days × Clear all

NCT05332210 2026-04-28

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Phase 3 Completed

Myasthenia Gravis